A clinical trial demonstrates that LiveSpo Navax, a nasal spray containing Bacillus spores, effectively reduces symptoms of acute rhinosinusitis (ARS) and acute otitis media (AOM) in children within 3-7 days. The treatment showed significant reductions in bacterial load and inflammatory markers while maintaining higher immunoglobulin A levels compared to standard care, offering a potential alternative to antibiotics.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.